Hemay005 not checked
Ganzhou Hemay Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
9 active
23 in total · 6 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants receive treatment with Hemay005 tablet during the Maintenance Phase (week M-0\~M-40).”In the company’s words, NCT07650942 on ClinicalTrials.gov
- Tested for
- Behçet's Disease, Ulcerative Colitis (UC), Moderate to Severe Ulcerative Colitis, COPD (Chronic Obstructive Pulmonary Disease), Psoriasis
- Main trialPhase 3
- “This is a phase 3, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 40 weeks and a follow up phase for 4weeks.”In the company’s words, NCT06145893 on ClinicalTrials.gov
- Other names
- Mufemilast · No other intervention name.
Other drugs for Behçet's Disease
- ApremilastAmgen · Phase 3
- RAY121Roche · Phase 1
Coming up3
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 May 2026 | A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease | |
| Phase 3Not yet recruiting | May 2028 | Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Active, not recruiting | 30 Dec 2026 | Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis | |
| Phase 2Not yet recruiting | 31 Dec 2027 | A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD | |
| Phase 1Recruiting | 10 Dec 2025 | To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage | |
| Phase 3Completed | 25 Oct 2022 | A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis | |
| Phase 2Completed | 12 Oct 2020 | Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis | |
| Phase 2Terminated | 30 Apr 2022 | A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease | |
| Phase 2Completed | 18 Aug 2023 | Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis | |
| Phase 2Completed | 24 Jan 2024 | A Study of Hemay005 in Adult With Atopic Dermatitis | |
| Phase 1Completed | 1 Aug 2021 | Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects | |
| Phase 1Completed | 1 Sep 2022 | In Vivo Mass Balance Study of [14C]Hemay005 | |
| Phase 1Completed | 8 Aug 2023 | A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers | |
| Phase 1Completed | 30 Sep 2024 | Bioequivalence Test of Hemay005 Tablets | |
| Phase 1Completed | 20 Jan 2025 | Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets | |
| Phase 1Completed | 16 Apr 2025 | To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment | |
| Phase 1Completed | 3 Jun 2025 | Evaluation the Safety of hemay005 Tablets | |
| Phase 3Authorised | not given | A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | |
| Phase 3Authorised | not given | A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by birch pollen exposure | |
| Phase 3/4Ended | not given | The effects of the manipulation of 5-HT, DA and NA on exercise-induced fatigue and brain activation | |
| Phase 2Not authorised | not given | A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE | |
| Phase 2Authorised | not given | Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial | |
| Phase 3Authorised | not given | Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026